PubMed

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.

Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M.

Diabetes Care. 2002 Aug;25(8):1398-404.PMID: 12145241 [PubMed - indexed for MEDLINE]Related articlesFree article

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M.

Diabetologia. 2002 Feb;45(2):195-202.PMID: 11935150 [PubMed - indexed for MEDLINE]Related articles

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.

Diabetes. 2004 May;53(5):1187-94.PMID: 15111485 [PubMed - indexed for MEDLINE]Related articlesFree article

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

Larsen J, Hylleberg B, Ng K, Damsbo P.

Diabetes Care. 2001 Aug;24(8):1416-21.PMID: 11473079 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Bush MA; Albiglutide Study Group.

J Clin Endocrinol Metab. 2008 Dec;93(12):4810-7. Epub 2008 Sep 23.PMID: 18812476 [PubMed - indexed for MEDLINE]Related articles

Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.

Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S.

Int J Clin Pharmacol Ther. 2008 Jun;46(6):273-9.PMID: 18541123 [PubMed - indexed for MEDLINE]Related articles

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.

Agersø H, Vicini P.

Eur J Pharm Sci. 2003 Jun;19(2-3):141-50.PMID: 12791417 [PubMed - indexed for MEDLINE]Related articles

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects.

Tiessen RG, Castaigne JP, Dreyfus JF, Nemansky M, Kruizinga HH, van Vliet AA.

Int J Clin Pharmacol Ther. 2008 Sep;46(9):443-52.PMID: 18793574 [PubMed - indexed for MEDLINE]Related articles

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB.

Diabetes. 2003 Jul;52(7):1786-91.PMID: 12829647 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.PMID: 16490580 [PubMed - indexed for MEDLINE]Related articles

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.PMID: 16912128 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.

Clin Ther. 2008 Oct;30(10):1817-30.PMID: 19014837 [PubMed - indexed for MEDLINE]Related articles

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.

Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, Westergaard L, Deacon CF, Knudsen LB.

Eur J Pharmacol. 2002 Sep 13;451(2):217-25.PMID: 12231394 [PubMed - indexed for MEDLINE]Related articles

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

Diabet Med. 2005 Aug;22(8):1016-23.PMID: 16026367 [PubMed - indexed for MEDLINE]Related articles

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M.

Diabetes. 2001 Nov;50(11):2530-9.PMID: 11679431 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder H, Nielsen L, Tu DT, Astrup A.

Diabetes Care. 2004 Aug;27(8):1915-21.PMID: 15277417 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.

Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.

Clin Ther. 2008 Mar;30(3):513-27.PMID: 18405789 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.

Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA.

Clin Pharmacol Ther. 2005 Dec;78(6):675-88.PMID: 16338283 [PubMed - indexed for MEDLINE]Related articles